Early intervention with liraglutide improves glucose tolerance without affecting islet microcirculation in young Goto–Kakizaki rats
Authors:
- 1 August 2012
- journal article
- research article
- Published by Elsevier in Regulatory Peptides
- Vol. 177 (1-3) , 92-96
Abstract
No abstract availableKeywords
Funding Information
- Novo Nordisk
- Chinese Diabetes Society
- Eli Lilly and Company
- European Foundation for the Study of Diabetes
This publication has 28 references indexed in Scilit:
- Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet NeedsPharmaceuticals, 2010
- The GK rat beta-cell: A prototype for the diseased human beta-cell in type 2 diabetes?Molecular and Cellular Endocrinology, 2009
- Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto–Kakizaki ratsClinical Science, 2008
- Effects of glucagon-like peptide-1-(7–36)-amide on pancreatic islet and intestinal blood perfusion in Wistar rats and diabetic GK ratsClinical Science, 2007
- Glycemic Durability of Rosiglitazone, Metformin, or Glyburide MonotherapyNew England Journal of Medicine, 2006
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Is Defective Pancreatic Beta-cell Mass Environmentally Programmed in Goto-Kakizaki Rat Model of Type 2 Diabetes?Pancreas, 2006
- Pancreatic islet blood flow is selectively enhanced by captopril, irbesartan and pravastatin, and suppressed by palmitateBiochemical and Biophysical Research Communications, 2006
- The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitroBiochemical and Biophysical Research Communications, 2005
- Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)The Lancet, 1998